<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5684">
  <stage>Registered</stage>
  <submitdate>28/04/2014</submitdate>
  <approvaldate>28/04/2014</approvaldate>
  <nctid>NCT02126540</nctid>
  <trial_identification>
    <studytitle>Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries</studytitle>
    <scientifictitle>A Non-randomized, Multi-center Feasibility Trial of the Avinger Pantheris System, an Atherectomy Device That Provides Directional Visualization and Imaging While Removing Plaque in Diseased Lower Extremity Arteries</scientifictitle>
    <utrn />
    <trialacronym>COMBINE-II</trialacronym>
    <secondaryid>P0638</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Peripheral Arterial Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Pantheris Atherectomy System

Experimental: Primary Cohort - Main cohort; treatment Arm with Pantheris Atherectomy System


Treatment: devices: Pantheris Atherectomy System
Treatment device in primary cohort arm; OCT image guided directional atherectomy

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary Safety Endpoint - The primary safety endpoint is defined as freedom from major adverse events (MAE) through 30 day follow-up:
Clinically driven target lesion revascularization (TLR)
Myocardial infarction (MI)
Cardiovascular related deaths
Unplanned, major index limb amputation
Device Related Events:
Clinically Significant Perforations
Clinically Significant Dissections
Clinically Significant Embolus
Pseudoaneurysm</outcome>
      <timepoint>Day 0 through Day 30</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Primary Effectiveness Endpoint - The primary efficacy endpoint of technical success is defined as the percent of target lesions that has a residual diameter stenosis &lt;50% post the Pantheris device alone as assessed by an independent review at the time of treatment using quantitative angiography or visual estimate.</outcome>
      <timepoint>Day 0</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary Safety Endpoint - Freedom from procedural emboli, defined as a new occlusion of any visualized runoff vessel which cannot be reversed with an intravascular vasodilator.</outcome>
      <timepoint>Day 0</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary Effectiveness Endpoint - Procedural success defined as the percent of target lesions that have residual diameter stenosis &lt; 30% post-Pantheris and any other adjunctive therapy.</outcome>
      <timepoint>Day 0</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary Effectiveness Endpoint - Ankle-Brachial Index at 30 days</outcome>
      <timepoint>Day 30</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary Effectiveness Endpoint - Rutherford Classification at 30 days.</outcome>
      <timepoint>Day 30</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Age = 18 years old.

          2. Patient is a candidate for percutaneous intervention for peripheral vascular disease
             in the legs.

          3. Patient is willing and able to give informed consent

          4. Documented symptomatic atherosclerotic peripheral vascular disease Rutherford
             Classification 2-5.

          5. Reference vessel lumen proximal to target lesion &gt;3.0 mm in diameter by visual
             estimation.

          6. Subject has de novo target lesion(s) with stenosis &gt;70% by visual estimation distal to
             the profunda femoral artery. No more than 2 lesions may be treated with the Pantheris
             device.

          7. Target lesion length &lt;10 cm if target lesion &gt;70% and &lt;99% stenosed. If target lesion
             a chronic total occlusion (99-100% stenosed), target lesion length &lt;4 cm.

          8. Patient is capable of meeting requirements and be present at the follow-up clinic
             visits at 30 days.

          9. At least one patent tibial run-off vessel at baseline. -</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Subject is pregnant or breast feeding.

          2. Rutherford Class 0 to 1 (asymptomatic and mild claudication).

          3. Rutherford Class 6 (critical limb ischemia).

          4. Severe calcification of the target lesion.

          5. Target lesion with any type of stent or graft.

          6. Target lesion in the iliac artery.

          7. Target lesion stenosis &lt;70%.

          8. Subjects with significant (&gt;70%) occlusive lesions proximal to the target lesion not
             successfully treated during the index procedure (upstream disease) and prior to
             treatment of the target lesion.

          9. Endovascular or surgical procedure performed on the index limb less than or equal to
             30 days prior to the index procedure.

         10. Planned endovascular or surgical procedure 30 days after the index procedure.

         11. Lesion in the contralateral limb requiring intervention during the index procedure or
             within 30 days of the index procedure.

         12. Subjects with active infections whether they are being currently treated or not.

         13. Hemodialysis or GFR &lt;30 mL/min or creatinine level &gt;2.5mg/dL.

         14. Evidence or history of intracranial or gastrointestinal bleeding, intracranial
             aneurysm, myocardial infarction or stroke within the past 2 months.

         15. Evidence or history of aneurysmal target vessel within the past 2 months.

         16. History of severe trauma, fracture, major surgery or biopsy of a parenchymal organ
             within the past 14 days.

         17. Known allergy to contrast agents or medications used to perform endovascular
             intervention that cannot be adequately pre-treated.

         18. Subjects in whom anti-platelet, anticoagulant, or thrombolytic therapy is
             contraindicated.

         19. History of heparin-induced thrombocytopenia (HIT).

         20. Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet
             count less than 125,000/mm2 , known coagulopathy, or INR &gt;1.5.

         21. Any thrombolytic therapy within 2 weeks of the index procedure.

         22. Any clinical and/or angiographic complication attributed to the use of another device
             prior to the insertion of the Pantheris into the subject.

         23. Subjects or their legal guardians who have not or will not sign the Informed Consent.

         24. Subjects who are unwilling or unable to comply with the follow-up study requirements.

         25. Participation in any study of an investigational device, medication, biologic or other
             agent within 30 days prior to enrollment that is either a cardiovascular study or
             could, in the judgment of the investigator, affect the results of the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/09/2015</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>0</actualsamplesize>
    <recruitmentstatus>Withdrawn</recruitmentstatus>
    <anticipatedlastvisitdate>1/07/2016</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Avinger, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To evaluate the safety and effectiveness of the Pantheris System to perform atherectomy while
      using directional visualization and imaging as an adjunct to fluoroscopy to aid removal of
      plaque from diseased lower extremity arteries.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02126540</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Andreq Holden, MD</name>
      <address>Auckland City Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>